Fig. 5
From: Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells
BMN-673 also synergizes with PRMT5 inhibitors. a A549 cells were treated for 7 days with DMSO, MS023 or either the PRMT5 inhibitor EPZ015666 or GSK-591 in presence of absence of BMN-673. Cell death was measured using the Viacount reagent (*p < 0.05; ***p < 0.001; ****p < 0.0001; two-way ANOVA). b Synergy map showing the interaction between EPZ15666 and BMN-673 in A549 cells. c Synergy map showing the interaction between GSK-591 and BMN-673 in A549 cells